Home / Health / Kids' Weight Drugs Surge: A 310x Rise
Kids' Weight Drugs Surge: A 310x Rise
4 Sep
Summary
- Weight-loss drug prescriptions for children aged 8-11 rose 310-fold.
- Nearly 94% of children on these drugs had severe obesity.
- Lifestyle measures remain the primary treatment for childhood obesity.
Prescribing of weight-loss drugs for children aged 8 to 11 has seen a dramatic increase. Between 2019 and 2026, the prevalence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prescriptions rose 310-fold, from 0.03% to 9.3% among eligible children. Despite this surge, only a small fraction of the studied children received these medications.
The study found that GLP-1 RAs were largely prescribed to children with severe obesity and related health issues. Nearly 94% of those on the drugs had severe obesity, compared to about 52% of non-users. Experts emphasize that lifestyle interventions like diet and exercise are fundamental, with medications considered as supplementary treatment.
These drugs are typically considered when children develop obesity-related complications or when lifestyle changes prove insufficient. The prescribing patterns also revealed disparities, with older children, girls, and those in less vulnerable areas being more likely to receive prescriptions, raising concerns about equitable access to care.
While preliminary data appear reassuring, longer-term follow-up is necessary to fully understand the risks and benefits of these medications in children. The potential harms of untreated childhood obesity, however, are significant, including conditions like type 2 diabetes and heart disease.
